Calcitonin gene-related peptide. A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.
Bethanechol compounds are parasympathomimetic agents that directly stimulate muscarinic receptors, primarily used to treat urinary retention and nonobstructive bladder dysfunction by increasing bladder contractility and decreasing post-void residual volume.
A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.
An eleven-amino acid neurotransmitter that appears in both the central and peripheral nervous systems. It is involved in transmission of PAIN, causes rapid contractions of the gastrointestinal smooth muscle, and modulates inflammatory and immune responses.
A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.
Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells.
An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS.
Slender processes of NEURONS, including the AXONS and their glial envelopes (MYELIN SHEATH). Nerve fibers conduct nerve impulses to and from the CENTRAL NERVOUS SYSTEM.
A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Cell surface proteins that bind calcitonin and trigger intracellular changes which influence the behavior of cells. Calcitonin receptors outside the nervous system mediate the role of calcitonin in calcium homeostasis. The role of calcitonin receptors in the brain is not well understood.
Cell surface proteins that bind CALCITONIN GENE-RELATED PEPTIDE with high affinity and trigger intracellular changes which influence the behavior of cells. CGRP receptors are present in both the CENTRAL NERVOUS SYSTEM and the periphery. They are formed via the heterodimerization of the CALCITONIN RECEPTOR-LIKE PROTEIN and RECEPTOR ACTIVITY-MODIFYING PROTEIN 1.
Tumors or cancer of the THYROID GLAND.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A receptor protein that is associated with RECEPTOR ACTIVITY-MODIFYING PROTEINS. When bound to RECEPTOR ACTIVITY-MODIFYING PROTEIN 1 it forms the CALCITONIN GENE-RELATED RECEPTOR. When bound to RECEPTOR ACTIVITY-MODIFYING PROTEIN 2 or RECEPTOR ACTIVITY-MODIFYING PROTEIN 3 it forms the ADRENOMEDULLIN RECEPTOR.
A molluscan neuroactive peptide which induces a fast excitatory depolarizing response due to direct activation of amiloride-sensitive SODIUM CHANNELS. (From Nature 1995; 378(6558): 730-3)
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
A category of nucleic acid sequences that function as units of heredity and which code for the basic instructions for the development, reproduction, and maintenance of organisms.
A method (first developed by E.M. Southern) for detection of DNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.
Peptides composed of between two and twelve amino acids.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A naturally occurring dipeptide neuropeptide found in muscles.
A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.
A ubiquitously expressed, secreted protein with bone resorption and renal calcium reabsorption activities that are similar to PARATHYROID HORMONE. It does not circulate in appreciable amounts in normal subjects, but rather exerts its biological actions locally. Overexpression of parathyroid hormone-related protein by tumor cells results in humoral calcemia of malignancy.
A 27-amino acid peptide with histidine at the N-terminal and isoleucine amide at the C-terminal. The exact amino acid composition of the peptide is species dependent. The peptide is secreted in the intestine, but is found in the nervous system, many organs, and in the majority of peripheral tissues. It has a wide range of biological actions, affecting the cardiovascular, gastrointestinal, respiratory, and central nervous systems.
The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.
A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.

Calcitonin gene-related peptide decreases expression of acetylcholinesterase in mammalian myotubes. (1/1567)

Nerve-derived trophic factors are known to modulate expression of acetylcholinesterase (AChE) in skeletal muscle fibers, yet the precise identity of these factors remains elusive. In the present study, we treated mouse C2 myotubes with calcitonin gene-related peptide (CGRP). Compared to non-treated myotubes, cell-associated AChE activity levels were decreased by approximately 60% after 48 h of treatment. A parallel reduction in AChE total protein levels was also observed as determined by Western blot analysis. The reduction in AChE activity was due to a decrease in the levels of the G1 molecular form and to an elimination of G1. By contrast, levels of secreted AChE remained unchanged following CGRP treatment. Finally, the overall decrease in AChE activity was accompanied by a reduction in AChE transcripts which could not be attributed to changes in the transcriptional rate of the ACHE gene.  (+info)

Interaction of amylin with calcitonin gene-related peptide receptors in the microvasculature of the hamster cheek pouch in vivo. (2/1567)

1. This study used intravital microscopy to investigate the receptors stimulated by amylin which shares around 50% sequence homology with the vasodilator calcitonin gene-related peptide (CGRP) in the hamster cheek pouch microvasculature in vivo. 2. Receptor agonists dilated arterioles (diameters 20-40 microm). The -log of the concentrations (+/- s.e.mean; n = 8) causing 50% increase in arteriole diameter were: human betaCGRP (10.8 +/- 0.3), human alphaCGRP (10.8 +/- 0.4), rat alphaCGRP (10.4 +/- 0.3). Rat amylin and the CGRP2 receptor selective agonist [Cys(ACM2,7]-human alphaCGRP were 100 fold less potent (estimates were 8.5 +/- 0.4 and 8.2 +/- 0.3 respectively). 3. The GCRP1 receptor antagonist, CGRP8-37 (300 nmol kg(-1); i.v.) reversibly inhibited the increase in diameter evoked by human alphaCGRP (0.3 nM) from 178 +/- 22% to 59 +/- 12% (n = 8; P < 0.05) and by rat amylin (100 nM) from 138 +/- 23% to 68 +/- 24% (n = 6; P < 0.05). CGRP8-37 did not inhibit vasodilation evoked by substance P (10 nM; n = 4: P > 0.05). 4. The amylin receptor antagonist, amylin8-37 (300 nmol kg(-1); i.v.) did not significantly inhibit the increase in diameter evoked by human alphaCGRP (0.3 nM) which was 112 +/- 26% in the absence, and 90 +/- 29% in the presence of antagonist (n = 4; P < 0.05); nor that evoked by rat amylin (100 nM) which was 146 +/- 23% in the absence and 144 +/- 32% in the presence of antagonist (n = 4; P > 0.05). 5. The agonist profile for vasodilatation and the inhibition of this dilatation by CGRP8-37, although not the amylin8-37 indicates that amylin causes vasodilatation through interaction with CGRP1 receptors in the hamster cheek pouch.  (+info)

Neurogenic origin of articular hyperemia in early degenerative joint disease. (3/1567)

It has been speculated that joint instability resulting from anterior cruciate ligament (ACL) rupture could be exacerbated by changes in vasomotor activity in the remaining supporting structures. In this study, the effect of ACL transection on medial collateral ligament (MCL) basal perfusion and its responsiveness to calcitonin gene-related peptide (CGRP) and sympathetic adrenergic influences was examined. Using urethan-anesthetized rabbits, we tested the effects of CGRP and its antagonist CGRP-(8-37) by topical application of these agents to the exposed knee while sympathetic influences were tested by electrically stimulating the saphenous nerve. It was found that MCL basal perfusion was elevated in ACL-sectioned joints; however, this effect was abrogated by prior resection of the articular nerve supply. At the doses tested, the normal vasodilator response to CGRP was abolished in ACL-sectioned joints, whereas the response to CGRP-(8-37) was attenuated. Even under the influence of increased constrictor tone, MCL and capsule blood vessels still showed substantially reduced responses to exogenous CGRP administration. By contrast, nerve-mediated constrictor responses were mostly unaffected by joint instability. This study suggests that posttraumatic knee joint hyperemia is neurogenically mediated, possibly by increased secretion of CGRP.  (+info)

Attenuation of myocardial injury due to oxygen free radicals (OFR) by pretreatment with OFR or calcitonin gene-related peptide. (4/1567)

AIM: To study the cardioprotective effects of oxygen free radicals (OFR) and calcitonin gene-related peptide (OGRP) pretreatment on myocardial damages due to OFR in isolated perfused rat heart. METHODS: The hearts were perfused in a Langendorff mode. OFR were generated by electrolysis of Krebs-Henseleit (K-H) solution. RESULTS: OFR pretreatment reduced the impairment of cardiac contractile function, the decrease of coronary flow and the increase of creatinine kinase (CK) release due to OFR, and the effect exhibited period dependence and cycle-dependence. 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7), an inhibitor of protein kinase C, abolished the protection of OFR pretreatment (CK release = 110 +/- 7, 215 +/- 23, 169 +/- 14, 240 +/- 30, and 113 +/- 19 kU.L-1 for control, OFR, OFR pretreatment, OFR pretreatment plus H-7, and H-7, respectively). CGRP pretreatment also protected the myocardium damages elicited by OFR in isolated perfused rat heart. CONCLUSIONS: OFR or CGRP pretreatment protected myocardium against injury elicited by OFR, and the effect of OFR pretreatment was related to the activation of PKC.  (+info)

Trigeminal nerve ganglion stimulation-induced neurovascular reflexes in the anaesthetized cat: role of endothelin(B) receptors in carotid vasodilatation. (5/1567)

1. The effects of intravenous administration of endothelin (ET) receptor antagonists SB-209670 (0.001-10.0 mg kg(-1)), SB-217242, SB-234551 (0.01-10.0 mg kg(-1)) and BQ-788 (0.001-1.0 mg kg(-1)) were investigated on trigeminal nerve ganglion stimulation-induced neurovascular reflexes in the carotid vasculature of the anaesthetized cat. Comparisons were made with sumatriptan (0.003-3.0 mg kg(-1)) and alpha-CGRP8-37 (0.001-0.1 mg kg(-1)). 2. Trigeminal nerve ganglion stimulation produced frequency related increases in carotid blood flow, reductions in carotid vascular resistance and non-frequency related increases in blood pressure. Guanethidine (3 mg kg(-1), i.v.) blocked trigeminal nerve ganglion-induced increases in blood pressure but had no effect on changes in carotid flow or resistance. Maximal reductions in carotid vascular resistance was observed at 10 Hz, and this frequency was selected to investigate the effects of drugs on trigeminal nerve ganglion stimulation-induced responses in guanethidine treated cats. 3. Saline, alpha-CGRP8-37 SB-209670 and BQ-788 had little or no effect on resting haemodynamic parameters. SB-217242 (10 mg kg(-1), n=3) produced a 56% reduction in arterial blood pressure whereas SB-233451 (10 mg kg(-1), n=3) produced a 30% reduction in carotid vascular resistance. Sumatriptan produced dose-related reductions in resting carotid flow and increases (max. 104% at 0.3 mg kg(-1), n = 5) in vascular resistance. 4. SB-209670 (n=6-7), SB-217242 (n=3) and BQ-788 (n=3) produced inhibition of trigeminal nerve ganglion stimulation-induced reductions in carotid vascular resistance. Saline, SB-234551, alpha-CGRP8-37 and sumatriptan had no effect. 5. These data demonstrate ET(B) receptor blockade attenuates the vasodilator effects of trigeminal nerve ganglion stimulation in the carotid vascular bed of guanethidine pretreated anaesthetized cats.  (+info)

Depletion of cutaneous peptidergic innervation in HIV-associated xerosis. (6/1567)

Severe xerosis occurs in approximately 20% of human immunodeficiency virus seropositive patients. Changes in cutaneous innervation have been found in various inflammatory skin diseases and in xerotic skin in familial amyloid. We have therefore carried out a quantitative examination of the cutaneous peptidergic innervation in human immunodeficiency virus-associated xerosis. Immunohistochemistry and image analysis quantitation were used to compare total cutaneous innervation (protein gene product 9.5), calcitonin gene-related peptide, substance P, and vasoactive intestinal peptide peptidergic fibers, at two sites in the skin of human immunodeficiency virus-associated xerosis patients (upper arm, n = 12; upper leg, n = 11) and site-matched seronegative controls (upper arm, n = 10; upper leg, n = 10). Measurement of lengths of fibers of each type was carried out for each subject in the epidermis and papillary dermis, and around the sweat glands. Immunostained mast cells in these areas were counted. Epidermal integrity and maturation were assessed by immunostaining for involucrin. There were significant (Mann-Whitney U test; p < 0.02) decreases in total lengths of protein gene product 9.5 fibers in both epidermis/papillary dermis and sweat gland fields; of calcitonin gene-related peptide innervation in the epidermis/papillary dermis; and of substance P innervation of the sweat glands. There were no differences in the distribution of mast cells, or in the epidermal expression of involucrin. Depletion of the calcitonin gene-related peptide innervation may affect the nutrient blood supply of the upper dermis, and the integrity and function of basal epidermis and Langerhans cells. Diminished substance P innervation of the sweat glands may affect their secretory activity. Both of these changes may be implicated in the development of xerosis.  (+info)

Decreased CGRP, but preserved Trk A immunoreactivity in nerve fibres in inflamed human superficial temporal arteries. (7/1567)

The peptidergic sensory innervation of cranial blood vessels may play an important part in vascular head pain. The neuropeptides calcitonin gene-related peptide (CGRP) and substance P in sensory fibres are dependent on nerve growth factor (NGF) produced by the blood vessels, and when released from nerve terminals mediate neurogenic inflammation. NGF is increased in inflamed tissues, and acts via its high affinity receptor trk A on nociceptor fibres to produce hyperalgesia. CGRP and trk A immunoreactive nerve fibres have therefore been studied, for the first time, in inflamed (n=7) and non-inflamed (n=10) temporal arteries biopsied from patients with headache and suspected giant cell arteritis. CGRP immunoreactivity was markedly decreased to absent in adventitial nerve fibres in inflamed regions of vessels, which may reflect secretion from nerve terminals, as CGRP immunoreactivity could still be seen in nerve trunks in periadventitial tissue. Trk A immunoreactive nerve fibres were found in a similar distribution to CGRP containing nerve fibres in non-inflamed vessels, and the trk A immunoreactivity was virtually unchanged in inflamed vessels. The evidence supports a role for NGF related mechanisms in inflammatory vascular head pain. Anti-NGF or anti-trk A agents may represent novel analgesics in this condition.  (+info)

Calcitonin gene-related peptide rapidly downregulates nicotinic receptor function and slowly raises intracellular Ca2+ in rat chromaffin cells in vitro. (8/1567)

Although calcitonin gene-related peptide (CGRP) modulates muscle-type nicotinic acetylcholine receptors (nAChRs) via intracellular second messenger-mediated phosphorylation, the action of this peptide on neuronal-type nAChRs remains unknown. Using neuronal nAChRs of rat chromaffin cells in vitro we studied the effect of CGRP, which is physiologically present in adrenal medulla, on membrane currents and [Ca2+]i transients elicited by nicotine. Our main novel observation was that CGRP (either bath-applied or focally applied for a few seconds or even co-applied with nicotine for a few milliseconds) selectively and rapidly blocked nAChRs (a phenomenon unlikely caused by intracellular messengers in view of its speed) without affecting GABA receptors. The inhibitory effect of CGRP was independent of [Ca2+]i or membrane potential and not accompanied by baseline current changes. Like the competitive antagonist N,N,N-trimethyl-1-(4-trans-stilbenoxy)-2-propilammonium, CGRP induced a rightward, parallel shift of the nicotine dose-response curve; during co-application of these blockers the nicotine dose-ratio value was the sum of the values obtained with each antagonist alone. The block by CGRP was insensitive to the receptor antagonist hCGRP8-37 but mimicked by CGRP1-7. Persistent application of CGRP slowly increased [Ca2+]i, a phenomenon independent from external Ca2+, thus implying Ca2+ release from internal stores, and suppressed by hCGRP8-37. CGRP1-7 had no significant effect on [Ca2+]i. We propose that the 1-7 amino acid sequence of CGRP was responsible for the direct, rapid block of nAChRs, whereas the full-length peptide molecule was necessary for the delayed rise in internal Ca2+ potentially able to trigger phosphorylation-dependent modulation of nicotinic receptor function.  (+info)

Calcitonin gene-related peptide (CGRP) is a neurotransmitter and vasodilator peptide that is widely distributed in the nervous system. It is encoded by the calcitonin gene, which also encodes calcitonin and catestatin. CGRP is produced and released by sensory nerves and plays important roles in pain transmission, modulation of inflammation, and regulation of blood flow.

CGRP exists as two forms, α-CGRP and β-CGRP, which differ slightly in their amino acid sequences but have similar biological activities. α-CGRP is found primarily in the central and peripheral nervous systems, while β-CGRP is expressed mainly in the gastrointestinal tract.

CGRP exerts its effects by binding to specific G protein-coupled receptors, which are widely distributed in various tissues, including blood vessels, smooth muscles, and sensory neurons. Activation of CGRP receptors leads to increased intracellular cyclic AMP levels, activation of protein kinase A, and subsequent relaxation of vascular smooth muscle, resulting in vasodilation.

CGRP has been implicated in several clinical conditions, including migraine, cluster headache, and inflammatory pain. Inhibition of CGRP signaling has emerged as a promising therapeutic strategy for the treatment of these disorders.

Calcitonin is a hormone that is produced and released by the parafollicular cells (also known as C cells) of the thyroid gland. It plays a crucial role in regulating calcium homeostasis in the body. Specifically, it helps to lower elevated levels of calcium in the blood by inhibiting the activity of osteoclasts, which are bone cells that break down bone tissue and release calcium into the bloodstream. Calcitonin also promotes the uptake of calcium in the bones and increases the excretion of calcium in the urine.

Calcitonin is typically released in response to high levels of calcium in the blood, and its effects help to bring calcium levels back into balance. In addition to its role in calcium regulation, calcitonin may also have other functions in the body, such as modulating immune function and reducing inflammation.

Clinically, synthetic forms of calcitonin are sometimes used as a medication to treat conditions related to abnormal calcium levels, such as hypercalcemia (high blood calcium) or osteoporosis. Calcitonin can be administered as an injection, nasal spray, or oral tablet, depending on the specific formulation and intended use.

Bethanechol compounds are a type of cholinergic agent used in medical treatment. They are parasympathomimetic drugs, which means they mimic the actions of the neurotransmitter acetylcholine at muscarinic receptors. Specifically, bethanechol compounds stimulate the muscarinic receptors in the smooth muscle of the bladder and gastrointestinal tract, increasing tone and promoting contractions.

Bethanechol is primarily used to treat urinary retention and associated symptoms, such as those that can occur after certain types of surgery or with conditions like spinal cord injury or multiple sclerosis. It works by helping the bladder muscle contract, which can promote urination.

It's important to note that bethanechol should be used with caution, as it can have various side effects, including sweating, increased salivation, flushed skin, and gastrointestinal symptoms like nausea, vomiting, or diarrhea. It may also interact with other medications, so it's crucial to discuss any potential risks with a healthcare provider before starting this treatment.

Bethanechol is a parasympathomimetic drug, which means it stimulates the parasympathetic nervous system. This system is responsible for regulating many automatic functions in the body, including digestion and urination. Bethanechol works by causing the smooth muscles of the bladder to contract, which can help to promote urination in people who have difficulty emptying their bladder completely due to certain medical conditions such as surgery, spinal cord injury, or multiple sclerosis.

The medical definition of 'Bethanechol' is:

A parasympathomimetic agent that stimulates the muscarinic receptors of the autonomic nervous system, causing contraction of smooth muscle and increased secretion of exocrine glands. It is used to treat urinary retention and associated symptoms, such as those caused by bladder-neck obstruction due to prostatic hypertrophy or neurogenic bladder dysfunction. Bethanechol may also be used to diagnose urinary tract obstruction and to test the integrity of the bladder's innervation.

Substance P is an undecapeptide neurotransmitter and neuromodulator, belonging to the tachykinin family of peptides. It is widely distributed in the central and peripheral nervous systems and is primarily found in sensory neurons. Substance P plays a crucial role in pain transmission, inflammation, and various autonomic functions. It exerts its effects by binding to neurokinin 1 (NK-1) receptors, which are expressed on the surface of target cells. Apart from nociception and inflammation, Substance P is also involved in regulating emotional behaviors, smooth muscle contraction, and fluid balance.

Neuropeptide Y (NPY) is a neurotransmitter and neuropeptide that is widely distributed in the central and peripheral nervous systems. It is a member of the pancreatic polypeptide family, which includes peptide YY and pancreatic polypeptide. NPY plays important roles in various physiological functions such as energy balance, feeding behavior, stress response, anxiety, memory, and cardiovascular regulation. It is involved in the modulation of neurotransmitter release, synaptic plasticity, and neural development. NPY is synthesized from a larger precursor protein called prepro-NPY, which is post-translationally processed to generate the mature NPY peptide. The NPY system has been implicated in various pathological conditions such as obesity, depression, anxiety disorders, hypertension, and drug addiction.

Neuropeptides are small protein-like molecules that are used by neurons to communicate with each other and with other cells in the body. They are produced in the cell body of a neuron, processed from larger precursor proteins, and then transported to the nerve terminal where they are stored in secretory vesicles. When the neuron is stimulated, the vesicles fuse with the cell membrane and release their contents into the extracellular space.

Neuropeptides can act as neurotransmitters or neuromodulators, depending on their target receptors and the duration of their effects. They play important roles in a variety of physiological processes, including pain perception, appetite regulation, stress response, and social behavior. Some neuropeptides also have hormonal functions, such as oxytocin and vasopressin, which are produced in the hypothalamus and released into the bloodstream to regulate reproductive and cardiovascular function, respectively.

There are hundreds of different neuropeptides that have been identified in the nervous system, and many of them have multiple functions and interact with other signaling molecules to modulate neural activity. Dysregulation of neuropeptide systems has been implicated in various neurological and psychiatric disorders, such as chronic pain, addiction, depression, and anxiety.

Capsaicin is defined in medical terms as the active component of chili peppers (genus Capsicum) that produces a burning sensation when it comes into contact with mucous membranes or skin. It is a potent irritant and is used topically as a counterirritant in some creams and patches to relieve pain. Capsaicin works by depleting substance P, a neurotransmitter that relays pain signals to the brain, from nerve endings.

Here is the medical definition of capsaicin from the Merriam-Webster's Medical Dictionary:

caпсаісіn : an alkaloid (C18H27NO3) that is the active principle of red peppers and is used in topical preparations as a counterirritant and analgesic.

Nerve fibers are specialized structures that constitute the long, slender processes (axons) of neurons (nerve cells). They are responsible for conducting electrical impulses, known as action potentials, away from the cell body and transmitting them to other neurons or effector organs such as muscles and glands. Nerve fibers are often surrounded by supportive cells called glial cells and are grouped together to form nerve bundles or nerves. These fibers can be myelinated (covered with a fatty insulating sheath called myelin) or unmyelinated, which influences the speed of impulse transmission.

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid polypeptide hormone that has potent vasodilatory, secretory, and neurotransmitter effects. It is widely distributed throughout the body, including in the gastrointestinal tract, where it is synthesized and released by nerve cells (neurons) in the intestinal mucosa. VIP plays a crucial role in regulating various physiological functions such as intestinal secretion, motility, and blood flow. It also has immunomodulatory effects and may play a role in neuroprotection. High levels of VIP are found in the brain, where it acts as a neurotransmitter or neuromodulator and is involved in various cognitive functions such as learning, memory, and social behavior.

Peptides are short chains of amino acid residues linked by covalent bonds, known as peptide bonds. They are formed when two or more amino acids are joined together through a condensation reaction, which results in the elimination of a water molecule and the formation of an amide bond between the carboxyl group of one amino acid and the amino group of another.

Peptides can vary in length from two to about fifty amino acids, and they are often classified based on their size. For example, dipeptides contain two amino acids, tripeptides contain three, and so on. Oligopeptides typically contain up to ten amino acids, while polypeptides can contain dozens or even hundreds of amino acids.

Peptides play many important roles in the body, including serving as hormones, neurotransmitters, enzymes, and antibiotics. They are also used in medical research and therapeutic applications, such as drug delivery and tissue engineering.

Calcitonin receptors (CTRs) are a type of G protein-coupled receptor (GPCR) that bind and respond to the hormone calcitonin. Calcitonin is a peptide hormone secreted by the parafollicular cells (C cells) of the thyroid gland, and plays a crucial role in regulating calcium homeostasis in the body.

CTRs are widely expressed in various tissues and organs, including bone, kidney, intestine, and brain. In bone, CTR activation inhibits osteoclast-mediated bone resorption, thereby increasing bone density and reducing the risk of fractures. In the kidney, CTR activation promotes calcium reabsorption and phosphate excretion, helping to maintain normal serum calcium and phosphate levels.

CTRs are also involved in various physiological processes, such as nociception (pain perception), neuroprotection, and cell proliferation and differentiation. Dysregulation of CTR signaling has been implicated in several diseases, including osteoporosis, hypercalcemia, and cancer.

The medical definition of "Receptors, Calcitonin" refers to the specific proteins that bind calcitonin hormone and mediate its effects on target cells and tissues.

Calcitonin gene-related peptide (CGRP) receptors are a type of cell surface receptor found in various tissues and cells, including the nervous system and blood vessels. CGRP is a neuropeptide that plays a role in regulating vasodilation, inflammation, and nociception (the sensation of pain).

The CGRP receptor is a complex of two proteins: calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). When CGRP binds to the CLR-RAMP1 complex, it activates a signaling pathway that leads to vasodilation and increased pain sensitivity.

CGRP receptors have been identified as important targets for the treatment of migraine headaches, as CGRP levels are known to increase during migraine attacks. Several drugs that target CGRP receptors have been developed and approved for the prevention and acute treatment of migraines.

Thyroid neoplasms refer to abnormal growths or tumors in the thyroid gland, which can be benign (non-cancerous) or malignant (cancerous). These growths can vary in size and may cause a noticeable lump or nodule in the neck. Thyroid neoplasms can also affect the function of the thyroid gland, leading to hormonal imbalances and related symptoms. The exact causes of thyroid neoplasms are not fully understood, but risk factors include radiation exposure, family history, and certain genetic conditions. It is important to note that most thyroid nodules are benign, but a proper medical evaluation is necessary to determine the nature of the growth and develop an appropriate treatment plan.

A peptide fragment is a short chain of amino acids that is derived from a larger peptide or protein through various biological or chemical processes. These fragments can result from the natural breakdown of proteins in the body during regular physiological processes, such as digestion, or they can be produced experimentally in a laboratory setting for research or therapeutic purposes.

Peptide fragments are often used in research to map the structure and function of larger peptides and proteins, as well as to study their interactions with other molecules. In some cases, peptide fragments may also have biological activity of their own and can be developed into drugs or diagnostic tools. For example, certain peptide fragments derived from hormones or neurotransmitters may bind to receptors in the body and mimic or block the effects of the full-length molecule.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

Calcitonin receptor-like protein (CRLR) is a gene that encodes for a protein involved in the regulation of various physiological functions, including cell proliferation, differentiation, and apoptosis. CRLR itself does not bind to calcitonin or any other ligands, but it serves as a necessary component for the formation of functional receptors for certain peptide hormones, such as calcitonin gene-related peptide (CGRP) and adrenomedullin.

These hormones play important roles in regulating blood pressure, inflammation, and nociception (the perception of pain). CRLR forms a complex with receptor activity-modifying proteins (RAMPs) to create functional receptors for CGRP and adrenomedullin. The specific combination of CRLR and RAMPs determines the type of receptor formed, which in turn dictates the ligand specificity and downstream signaling pathways activated.

Mutations in the CRLR gene have been associated with various diseases, including familial hypocalciuric hypercalcemia (FHH) type 3, a rare inherited disorder characterized by elevated serum calcium levels and decreased urinary calcium excretion. Additionally, dysregulation of CRLR-mediated signaling pathways has been implicated in the development and progression of several types of cancer, neurodegenerative disorders, and cardiovascular diseases.

FMRFamide is not a medical term per se, but it is a neuropeptide that was first identified in the clam, Mytilus edulis. FMRFamide stands for Phe-Met-Arg-Phe-NH2, which are its five amino acid residues. It functions as a neurotransmitter or neuromodulator in various organisms, including humans. In mammals, related peptides are involved in the regulation of several physiological processes such as cardiovascular function, feeding behavior, and nociception (pain perception).

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

A gene is a specific sequence of nucleotides in DNA that carries genetic information. Genes are the fundamental units of heredity and are responsible for the development and function of all living organisms. They code for proteins or RNA molecules, which carry out various functions within cells and are essential for the structure, function, and regulation of the body's tissues and organs.

Each gene has a specific location on a chromosome, and each person inherits two copies of every gene, one from each parent. Variations in the sequence of nucleotides in a gene can lead to differences in traits between individuals, including physical characteristics, susceptibility to disease, and responses to environmental factors.

Medical genetics is the study of genes and their role in health and disease. It involves understanding how genes contribute to the development and progression of various medical conditions, as well as identifying genetic risk factors and developing strategies for prevention, diagnosis, and treatment.

Southern blotting is a type of membrane-based blotting technique that is used in molecular biology to detect and locate specific DNA sequences within a DNA sample. This technique is named after its inventor, Edward M. Southern.

In Southern blotting, the DNA sample is first digested with one or more restriction enzymes, which cut the DNA at specific recognition sites. The resulting DNA fragments are then separated based on their size by gel electrophoresis. After separation, the DNA fragments are denatured to convert them into single-stranded DNA and transferred onto a nitrocellulose or nylon membrane.

Once the DNA has been transferred to the membrane, it is hybridized with a labeled probe that is complementary to the sequence of interest. The probe can be labeled with radioactive isotopes, fluorescent dyes, or chemiluminescent compounds. After hybridization, the membrane is washed to remove any unbound probe and then exposed to X-ray film (in the case of radioactive probes) or scanned (in the case of non-radioactive probes) to detect the location of the labeled probe on the membrane.

The position of the labeled probe on the membrane corresponds to the location of the specific DNA sequence within the original DNA sample. Southern blotting is a powerful tool for identifying and characterizing specific DNA sequences, such as those associated with genetic diseases or gene regulation.

Oligopeptides are defined in medicine and biochemistry as short chains of amino acids, typically containing fewer than 20 amino acid residues. These small peptides are important components in various biological processes, such as serving as signaling molecules, enzyme inhibitors, or structural elements in some proteins. They can be found naturally in foods and may also be synthesized for use in medical research and therapeutic applications.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Carnosine is a dipeptide molecule composed of the amino acids histidine and alanine, which is naturally found in high concentrations in certain tissues of the body, particularly in muscle and brain tissue. It acts as an antioxidant, helping to protect cells from damage caused by free radicals and other oxidative stressors. Carnosine also has anti-glycation properties, meaning it helps prevent the formation of advanced glycation end products (AGEs) that can contribute to aging and age-related diseases. Additionally, carnosine has been shown to have potential benefits in neuroprotection, cardioprotection, and anti-inflammation. It is being studied for its potential therapeutic uses in various health conditions, including diabetes, cataracts, Alzheimer's disease, and other neurological disorders.

A peptide library is a collection of a large number of peptides, which are short chains of amino acids. Each peptide in the library is typically composed of a defined length and sequence, and may contain a variety of different amino acids. Peptide libraries can be synthesized using automated techniques and are often used in scientific research to identify potential ligands (molecules that bind to specific targets) or to study the interactions between peptides and other molecules.

In a peptide library, each peptide is usually attached to a solid support, such as a resin bead, and the entire library can be created using split-and-pool synthesis techniques. This allows for the rapid and efficient synthesis of a large number of unique peptides, which can then be screened for specific activities or properties.

Peptide libraries are used in various fields such as drug discovery, proteomics, and molecular biology to identify potential therapeutic targets, understand protein-protein interactions, and develop new diagnostic tools.

Parathyroid Hormone-Related Protein (PTHrP) is a protein that is encoded by the PTHLH gene in humans. It is structurally similar to parathyroid hormone (PTH) and was initially identified due to its role in humoral hypercalcemia of malignancy, a condition characterized by high levels of calcium in the blood caused by certain types of cancer.

PTHrP has a variety of functions in the body, including regulation of calcium and phosphate homeostasis, cell growth and differentiation, and bone metabolism. It acts through a specific G protein-coupled receptor called the PTH/PTHrP receptor, which is found in many tissues throughout the body, including bone, kidney, and cartilage.

In contrast to PTH, which is primarily produced by the parathyroid glands and regulates calcium levels in the blood, PTHrP is produced by many different types of cells throughout the body. Its expression is regulated in a tissue-specific manner, and its functions can vary depending on the context in which it is produced.

Overall, PTHrP plays important roles in normal physiology as well as in various disease states, including cancer, bone disorders, and developmental abnormalities.

I'm sorry for the confusion, but "Peptide PHI" is not a widely recognized or established medical term. It seems that there might be some misunderstanding or miscommunication related to this term.

If you are referring to a specific type of peptide or a research study, could you please provide more context or clarify the source of the term? I would be happy to help you with accurate and reliable information once I have a better understanding of what you are asking about.

Genetic transcription is the process by which the information in a strand of DNA is used to create a complementary RNA molecule. This process is the first step in gene expression, where the genetic code in DNA is converted into a form that can be used to produce proteins or functional RNAs.

During transcription, an enzyme called RNA polymerase binds to the DNA template strand and reads the sequence of nucleotide bases. As it moves along the template, it adds complementary RNA nucleotides to the growing RNA chain, creating a single-stranded RNA molecule that is complementary to the DNA template strand. Once transcription is complete, the RNA molecule may undergo further processing before it can be translated into protein or perform its functional role in the cell.

Transcription can be either "constitutive" or "regulated." Constitutive transcription occurs at a relatively constant rate and produces essential proteins that are required for basic cellular functions. Regulated transcription, on the other hand, is subject to control by various intracellular and extracellular signals, allowing cells to respond to changing environmental conditions or developmental cues.

Bombesin is a type of peptide that occurs naturally in the body. It is a small protein-like molecule made up of amino acids, and it is involved in various physiological processes, including regulating appetite and digestion. Bombesin was first discovered in the skin of a frog species called Bombina bombina, hence its name. In the human body, bombesin-like peptides are produced by various tissues, including the stomach and brain. They bind to specific receptors in the body, triggering a range of responses, such as stimulating the release of hormones and increasing gut motility. Bombesin has been studied for its potential role in treating certain medical conditions, including cancer, although more research is needed to establish its safety and efficacy.

... (CGRP) is a member of the calcitonin family of peptides consisting of calcitonin, amylin, ... Regulation of the calcitonin gene-related peptide (CGRP) gene is in part controlled by the expression of the mitogen-activated ... The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors". Pharmacological Reviews. 54 ... Calcitonin+Gene-Related+Peptide at the U.S. National Library of Medicine Medical Subject Headings (MeSH) (CS1: long volume ...
Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drugs that act as antagonists of the calcitonin gene ... v t e (CS1 German-language sources (de), Antimigraine drugs, Receptor antagonists, Calcitonin gene-related peptide receptor ... an Oral Calcitonin Gene Related Peptide Receptor Antagonist". British Journal of Clinical Pharmacology. 79 (5): 831-7. doi: ... "Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies ...
Fenethylline Theodrenaline Morton IK, Hall JM (1999). "Calcitonin gene-related peptide receptor antagonist". Concise Dictionary ...
Maayan C, Becker Y, Gesundheit B, Girgis SI (2002). "Calcitonin gene related peptide in familial dysautonomia". Neuropeptides. ... April 1996). "Human CAAF1 gene--molecular cloning, gene structure, and chromosome mapping". Biochemical and Biophysical ... gene, a new member of the S100 gene cluster on chromosome 1q21". Cell Calcium. 20 (6): 459-64. doi:10.1016/S0143-4160(96)90087- ... gene, a new member of the S100 gene cluster on chromosome 1q21". Cell Calcium. 20 (6): 459-64. doi:10.1016/S0143-4160(96)90087- ...
Brain, S. D.; Williams, T. J.; Tippins, J. R.; Morris, H. R.; MacIntyre, I. (1985). "Calcitonin gene-related peptide is a ... In her early career she discovered the Calcitonin gene-related peptide receptor antagonist (CGRP) as a potent microvascular ... More recently her research found that the gene TRPC5 can help protect against pain in arthritis and that the gene TRPA1 is ...
ACh-vasoactive intestinal peptide (VIP) co-release. ACh-calcitonin gene-related peptide (CGRP) co-release. Glutamate-dynorphin ... For example, striatal "GABAergic neurons" utilize opioid peptides or substance P as their primary cotransmitter. Some neurons ...
They are calcitonin gene-related peptide (CGRP) receptor antagonists. Gepants have been suggested to have less pain relief at 2 ... and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies". Pharmaceutics. 12 (12): 1180. doi:10.3390/ ... The exact mechanism of action is unknown but seems to be related to serotonin's impact on migraine. In particular, ...
... it is a receptor for calcitonin gene-related peptide. The protein encoded by the CALCRL gene is a G protein-coupled receptor ... 2004). "Calcitonin gene-related peptide and its role in migraine pathophysiology". Eur J Pharmacol. 500 (1-3): 315-30. doi: ... Calcitonin gene-related peptide receptor antagonists are approved for the treatment of migraine. GRCh38: Ensembl release 89: ... 2003). "Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity". Trends Endocrinol. Metab. 13 (6 ...
... is a calcitonin gene-related peptide receptor antagonist. It is sprayed into the nose. It is sold by Pfizer. The ... Calcitonin gene-related peptide receptor antagonists, Pfizer brands, Piperazines, Piperidines, Indazoles, Quinolines, Ureas, ...
"Regulation of signal transduction by calcitonin gene-related peptide receptors." Trends in Pharmacological Sciences 31, no. 10 ... "Agonist-dependent consequences of proline to alanine substitution in the transmembrane helices of the calcitonin receptor." Br ... "Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes." Molecular Pharmacology ... Investigation of the calcitonin receptor-like receptor and receptor activity modifying proteins' at Imperial College London. ...
"Entrez Gene: RCP9 calcitonin gene-related peptide-receptor component protein". Yallampalli C, Chauhan M, Thota CS, et al. (2003 ... 2002). "Characterization of calcitonin gene-related peptide (CGRP) receptors and their receptor-activity-modifying proteins ( ... Luebke AE, Dahl GP, Roos BA, Dickerson IM (Jun 1996). "Identification of a protein that confers calcitonin gene-related peptide ... Balkan W, Oates EL, Howard GA, Roos BA (Mar 1999). "Testes exhibit elevated expression of calcitonin gene-related peptide ...
... is a small-molecule calcitonin gene-related peptide receptor antagonist. It is the first drug in this class approved ... January 2020). "Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin GeneRelated Peptide ... Calcitonin gene-related peptide receptor antagonists, Carboxamides, Trifluoromethyl compounds, Spiro compounds, Piperidinones, ...
... calcitonin gene related peptide). Examples of alternative splicing in immunoglobin gene transcripts in mammals were also ... The gene encoding the thyroid hormone calcitonin was found to be alternatively spliced in mammalian cells. The primary ... Rosenfeld MG, Amara SG, Roos BA, Ong ES, Evans RM (March 1981). "Altered expression of the calcitonin gene associated with RNA ... Rosenfeld MG, Lin CR, Amara SG, Stolarsky L, Roos BA, Ong ES, Evans RM (March 1982). "Calcitonin mRNA polymorphism: peptide ...
"A cDNA encoding the calcitonin gene-related peptide type 1 receptor". J Biol Chem. 271 (19): 11325-9. doi:10.1074/jbc.271.19. ... Lesche R, Peetz A, van der Hoeven F, Rüther U (1998). "Ft1, a novel gene related to ubiquitin-conjugating enzymes, is deleted ... AKT-interacting protein is a protein that in humans is encoded by the AKTIP gene. The mouse homolog of this gene produces fused ... This gene may play a role in apoptosis as these morphological abnormalities are caused by altered patterns of programmed cell ...
The calcitonin gene-related peptide (CGRP) is a therapeutic target in migraine because of its hypothesized role in mediating ... In turn, histamine evokes the release of substance P and calcitonin gene-related peptide; thus, a bidirectional link between ... Durham PL, Vause CV (July 2010). "Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine". ... Calcitonin Gene-Related Peptide (CGRP), neurokinin A (NKA), and endothelin-3 (ET-3). In such neurons, release of these pro- ...
It is in the calcitonin gene-related peptide antagonist class of medications. It was approved for medical use in the United ... Fremanezumab is a fully humanized monoclonal antibody directed against calcitonin gene-related peptides (CGRP) alpha and beta. ... Like other proteins, the substance is degraded by proteolysis to small peptides and amino acids, which are reused or excreted ...
... is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist. Rimegepant was developed by Biohaven ... Calcitonin gene-related peptide receptor antagonists, Carbamates, Fluoroarenes, Heterocyclic compounds with 2 rings, Nitrogen ...
It is a gepant, an orally active calcitonin gene-related peptide receptor antagonist. The most common side effects include ... Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ (June 2020). "Gepants, calcitonin-gene-related peptide receptor antagonists: what ... Calcitonin gene-related peptide receptor antagonists, Carboxamides, Organofluorides, Piperidines, Pyridines, Pyrroles, Spiro ...
"Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure". Journal of the American ... Presented future investigative opportunities related to the Herceptin drug mechanism of action of, marking the start of the ... "Effects of prolonged infusions of atrial natriuretic peptide and isoproterenol on the mechanical and endocrine function of ... have led to significant changes in cardiology practice guidelines and resulted in the successful registration of related ...
Along with H. R. Morris he isolated and sequenced calcitonin gene-related peptide. Later research centred on the role played by ... His team also demonstrated calcitonin gene-related peptide, which they went on to sequence and then characterise. A major ... "The myotropic and plasma-calcium modulating effects of calcitonin gene-related peptide (CGRP)". Neuropeptides. 4 (5): 425-434. ... Macintyre's laboratory also purified and then sequenced both porcine calcitonin and human calcitonin. ...
This stage is regulated by androgens, the genitofemoral nerve, and calcitonin gene-related peptide. During the second and third ... Studies of gene expression show that a specific complement of genes, such as follistatin and multiple cyclin kinase inhibitors ... Malformations in the GCM2 gene have resulted in hypoparathyroidism. Studies on SOX3 gene mutations have demonstrated that it ... which suggests the gene plays an important role in the development of the parathyroid gland. The genes, TBX1, CRKL, GATA3, GCM2 ...
This stage is regulated by androgens, the genitofemoral nerve, and calcitonin gene-related peptide. During the second and third ... Studies of gene expression show that a specific complement of genes, such as follistatin and multiple cyclin kinase inhibitors ... Studies in mice have shown that interfering with the HOX15 gene can cause parathyroid gland aplasia, which suggests the gene ... Malformations in the GCM2 gene have resulted in hypoparathyroidism. Studies on SOX3 gene mutations have demonstrated that it ...
Kameda Y (October 1987). "Localization of immunoreactive calcitonin gene-related peptide in thyroid C cells from various ... Parafollicular cells secrete calcitonin, a hormone that participates in the regulation of calcium metabolism. Calcitonin lowers ... The primary function of these cells is to secrete calcitonin. They are located adjacent to the thyroid follicles and reside in ... Gkonos PJ, Tavianini MA, Liu CC, Roos BA (December 1989). "Thyrotropin-releasing hormone gene expression in normal thyroid ...
... , sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR ... Erenumab is a fully human monoclonal antibody blocking the calcitonin gene-related peptide receptor (CGRPR). After subcutaneous ... Calcitonin gene-related peptide receptor antagonists, Monoclonal antibodies, Amgen, Novartis brands). ... Like other proteins, the substance is degraded by proteolysis to small peptides and amino acids. It has an elimination half- ...
Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature, 335(6191 ... Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proceedings of the ...
2004). "Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like ... CRLR, a receptor with seven transmembrane domains, can function as either a calcitonin gene-related peptide (CGRP) receptor or ... 2008). "Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide ... 2004). "Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity- ...
CRLR, a receptor with seven transmembrane domains, can function as either a calcitonin gene-related peptide (CGRP) receptor or ... 2008). "Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide ... 2004). "Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity- ... of the cytoplasmic tails of the human receptor activity-modifying protein components of calcitonin gene-related peptide and ...
... peptide histidine isoleucine, calcitonin gene-related peptide, substance P and somatostatin. Gross PM, Weindl A (1987). " ... Peptides. 31 (4): 757-76. doi:10.1016/j.peptides.2010.01.003. PMID 20093161. S2CID 44760261. Morita S.; Miyata S. (2012). " ... Other peptides aside from melatonin have been detected in the pineal. They are most likely associated with a type of ... Related to its secretory function, the SCO is partially composed of ependymal cells. These ependymocytes are characterized by ...
They can interact with neuropeptides (substance P) and calcitonin gene-related peptide (CGRP) during the inflammatory response ...
"Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like ... CALCRL, a receptor with seven transmembrane domains, can function as either a calcitonin gene-related peptide (CGRP) receptor ... 2008). "Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide ... 2004). "Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity- ...
Calcitonin gene-related peptide (CGRP) is a member of the calcitonin family of peptides consisting of calcitonin, amylin, ... Regulation of the calcitonin gene-related peptide (CGRP) gene is in part controlled by the expression of the mitogen-activated ... The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors". Pharmacological Reviews. 54 ... Calcitonin+Gene-Related+Peptide at the U.S. National Library of Medicine Medical Subject Headings (MeSH) (CS1: long volume ...
... H. ... TSW Collections: 4th International Meeting of the Calcitonin Gene-Related Peptide, 2001. View this Special Issue ...
The development and optimisation of an HPLC-based in vitro serum stability assay for a calcitonin gene-related peptide receptor ... The development and optimisation of an HPLC-based in vitro serum stability assay for a calcitonin gene-related peptide receptor ... and validation of a method for the evaluation of the stability of a lead calcitonin gene-related peptide antagonist peptide ( ... Evaluation of the stability of peptide drug candidates in biological fluids, such as blood serum, is of high importance during ...
Alpha-calcitonin gene-related peptide can reverse the catabolic influence of UHMWPE particles on RANKL expression in primary ... Background and purpose: A linkage between the neurotransmitter alpha-calcitonin gene-related peptide (alpha-CGRP) and particle- ...
title = "Calcium: Calcitonin gene-related peptide and adrenomedullin receptors",. abstract = "Calcitonin gene-related peptide ( ... Calcitonin gene-related peptide (CGRP), adrenomedullin (AM) and adrenomedullin 2 (AM2) are related peptides, which are potent ... N2 - Calcitonin gene-related peptide (CGRP), adrenomedullin (AM) and adrenomedullin 2 (AM2) are related peptides, which are ... AB - Calcitonin gene-related peptide (CGRP), adrenomedullin (AM) and adrenomedullin 2 (AM2) are related peptides, which are ...
Osteopontin oder Calcitonin-Gene-Related Peptide enthalten. Dissertation, LMU München: Faculty of Medicine ... Osteopontin oder Calcitonin-Gene-Related Peptide enthalten Trigeminale Afferenzen zu den äußeren Augenmuskeln des Rhesusaffen, ...
Other Names: alpha-Calcitonin Gene Related Peptide (19-37), human. Rovero, P.; et al., Peptides, 13, 1025, (1992). ... Home » Shop » Catalog Peptides » CGRP » alpha-CGRP (19-37), human [101233-12-9] ... Try our high quality amino acids, resins and reagents and see just how much better your peptides can be! ...
Dual action of the cannabinoid receptor 1 ligand arachidonyl-2′-chloroethylamide on calcitonin gene-related peptide release. ... on calcitonin gene-related peptide (CGRP) release in the dura and trigeminal ganglion (TG), as cannabinoids are known to ...
Dual action of the cannabinoid receptor 1 ligand arachidonyl-2′-chloroethylamide on calcitonin gene-related peptide release. * ... on calcitonin gene-related peptide (CGRP) release in the dura and trigeminal ganglion (TG), as cannabinoids are known to ... on calcitonin gene-related peptide (CGRP) release in the dura and trigeminal ganglion (TG), as cannabinoids are known to ... on calcitonin gene-related peptide (CGRP) release in the dura and trigeminal ganglion (TG), as cannabinoids are known to ...
calcitonin gene-related peptide, substance P, hypertension. in Blood Pressure. volume. 1. issue. 4. pages. 223 - 229. publisher ... Sensory nerve terminal activity in severe hypertension as reflected by circulating calcitonin gene-related peptide (CGRP) and ... calcitonin gene-related peptide; substance P; hypertension}}, language = {{eng}}, number = {{4}}, pages = {{223--229}}, ... Sensory nerve terminal activity in severe hypertension as reflected by circulating calcitonin gene-related peptide (CGRP) and ...
Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission. ...
Calcitonin Gene-Related Peptide Protects Against Cardiovascular Dysfunction Independently of Nitric Oxide In Vivo. / Argunhan, ... Calcitonin Gene-Related Peptide Protects Against Cardiovascular Dysfunction Independently of Nitric Oxide In Vivo. In: ... The neuropeptide CGRP (calcitonin gene-related peptide) is a potent vasodilator, with a cardioprotective role, although the ... Calcitonin Gene-Related Peptide Protects Against Cardiovascular Dysfunction Independently of Nitric Oxide In Vivo. Hypertension ...
Effects of calcitonin gene-related peptide on regeneration and reorganization of neoromuscular structures following peripheral ... Gunther, Elizabeth Ann, "Effects of calcitonin gene-related peptide on regeneration and reorganization of neoromuscular ...
Calcitonin gene-related peptide (CGRP) inhibitors. CGRP is a type of protein thats released in the brain and can affect ... 2020). Calcitonin gene-related peptide antagonists for the prevention of migraine: Highlights from pivotal studies and the ... 2021). Role of monoclonal antibodies against calcitonin gene-related peptide (CGRP) in episodic migraine prevention: Where do ... Magnesium. Magnesium may prevent some specific symptoms of migraine, such as aura and migraine episodes related to your periods ...
... Book Posting July 25, 2023. ... Overview of Calcitonin Gene-Related Peptide (CGRP) Mechanisms (2004) PDF free download: ... getButton} $text={Download Calcitonin Gene-Related Peptide (CGRP) Mechanisms (2004)} $icon={download} $color={Hex Color} ... getButton} $text={Download Calcitonin Gene-Related Peptide (CGRP) Mechanisms (2004)} $icon={download} $color={Hex Color} ...
Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects. Jason ... Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case ... Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine. Practical Neurology 2023;23:200-207. ...
Find 224-261-7 and related products for scientific research at Merck ... Calcitonin Gene-Related Peptide-I, Human. Synonym(s). : Calcitonin Gene-Related Peptide-I, Human ... Calcitonin Gene Related Peptide human. Synonym(s). : α-CGRP, CGRP-I. Empirical Formula (Hill Notation). : C163H267N51O49S2. CAS ... Calcitonin Gene-Related Peptide-I, Human, CAS 90954-53-3, is a potent and long-acting vasodilator. Increases plasma levels of ...
Differential effects of calcitonin gene-related peptide and calcitonin gene-related peptide 8-37 upon responses to N-methyl-d- ... Differential effects of calcitonin gene-related peptide and calcitonin gene-related peptide 8-37 upon responses to N-methyl-d- ...
Aging, Animals, Calcitonin Gene-Related Peptide; analysis/genetics, Fluorescent Antibody Technique, Gene Expression Regulation ... Developmentally regulated expression of calcitonin gene-related peptide at mammalian neuromuscular junction. M. Matteoli;BALBI ... In situ hybridization experiments have shown that the down-regulation of calcitonin gene-related peptide-like immunoreactivity ... In situ hybridization experiments have shown that the down-regulation of calcitonin gene-related peptide-like immunoreactivity ...
Esophageal mucosal blood flow : A central role for calcitonin gene-related peptide. In: Surgery. 1994 ; Vol. 116, No. 2. pp. ... Esophageal mucosal blood flow : A central role for calcitonin gene-related peptide. / McKie, L. D.; Dunkin, B. J.; Pennanen, M ... Esophageal mucosal blood flow: A central role for calcitonin gene-related peptide. Surgery. 1994;116(2):409-418. ... The purpose of this study was to determine whether substance P. calcitonin gene-related peptide (CGRP), or adenosine could ...
Calcitonin gene-related peptide (CGRP) is a 37 amino acid potent vasodilator with positive-ionotropic and -chronotropic effects ... Calcitonin gene-related peptide (CGRP) is a 37 amino acid potent vasodilator with positive-ionotropic and -chronotropic effects ... Calcitonin gene-related peptide (CGRP) is a 37 amino acid potent vasodilator with positive-ionotropic and -chronotropic effects ... Calcitonin gene-related peptide (CGRP) is a 37 amino acid potent vasodilator with positive-ionotropic and -chronotropic effects ...
CGRP release; calcitonin gene-related peptide; fremanezumab; migraine pain; monoclonal antibody; rat; trigeminal ganglion ... The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP ... In preclinical rat experiments, fremanezumab has been shown to reduce calcitonin gene-related peptide (CGRP) release from ... The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigemi ...
Calcitonin gene-related peptide (CGRP) promotes neuron recruitment and neurogenic activity. in. Posted bymindunwindart February ... Calcitonin gene-related peptide (CGRP) promotes neuron recruitment and neurogenic activity. in higher levels than the ... Leave a comment on Calcitonin gene-related peptide (CGRP) promotes neuron recruitment and neurogenic activity. in ... This vector contained the EGFP media reporter gene produced from pEGFP-C. The transfer vector pShuttle-CGRP was constructed ...
Drug class: calcitonin gene-related peptide (CGRP) antagonists. *Drug form: liquid solution in asingle-dose prefilled syringe ...
... such as substance P and calcitonin gene-related peptide (CGRP). The neurotransmitters mentioned above are released into the ... Relating to allostatic overload, an important role is played by psychosocial stress such as work overload, unemployment, or ... In fact, in the short term, these effects would not be consistent with the timing relating to matrix remodeling. If this were ... The loss of the collective oscillation of CD, related to the reduction of the thickness of EZs, would not allow the biological ...
The nociceptive effects of i.p administration of a synthetic peptide (CgA4-16) derived from chromogranin A (CgA) were studied ... Calcitonin Gene-Related Peptide / pharmacology * Calcium Channel Blockers / pharmacology * Calcium Channels, L-Type / drug ... the peptide increased the number of abdominal constrictions induced by i.p AA administration in a dose-related manner. To ... The effect of a chromogranin A-derived peptide (CgA4-16) in the writhing nociceptive response induced by acetic acid in rats ...
Evidence for decreased calcitonin gene-related peptide (CGRP) receptors and compromised responsiveness to CGRP of fetoplacental ... Dive into the research topics of Evidence for decreased calcitonin gene-related peptide (CGRP) receptors and compromised ...
... famous as a high-tech manufacturer in the peptide synthesis industry for supplying both generic peptide APIs and Custom peptide ... Custom Peptides * Custom Peptide Catalog * Vasoactive Intestinal Peptides (VIP) * Virus Related Peptides ... Custom Peptides * Custom Peptide Catalog * Vasoactive Intestinal Peptides (VIP) * Virus Related Peptides ... Custom Peptides * Custom Peptide Catalog * Vasoactive Intestinal Peptides (VIP) * Virus Related Peptides ...
Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and ... Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and ...
Calcitonin gene-related peptide (CGRP) or adrenomedullin (AM) receptors are heteromers of the calcitonin receptor-like receptor ... Adrenomedullin; Calcitonin gene-related peptide; GPCR; Receptor activity-modifying protein; Molecular modeling; Molecular ... activity-modifying protein dependent and independent activation mechanisms in the coupling of calcitonin gene-related peptide ... activity-modifying protein dependent and independent activation mechanisms in the coupling of calcitonin gene-related peptide ...

No FAQ available that match "calcitonin gene related peptide"

No images available that match "calcitonin gene related peptide"